SINOTHERAPEUTICS INC
GenericsSINOTHERAPEUTICS INC is a generic drug manufacturer focused on Cardiovascular, Immunology, Gastroenterology.
SINOTHERAPEUTICS INC's Key Drugs
SINOTHERAPEUTICS INC's core commercial portfolio centers on SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, spanning Cardiovascular and Immunology — its most strategically important drugs approved in the last 15 years.
SINOTHERAPEUTICS INC's Recent FDA Approvals
New NDA/BLA approvals for SINOTHERAPEUTICS INC over the last two years — novel drugs only, excluding generics and label supplements.
SINOTHERAPEUTICS INC's Therapeutic Areas
SINOTHERAPEUTICS INC's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SINOTHERAPEUTICS INC's Top Competitors
SINOTHERAPEUTICS INC's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Takeda, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SINOTHERAPEUTICS INC Pipeline Snapshot
Active clinical trials for SINOTHERAPEUTICS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SITAGLIPTIN AND METFORMIN HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2017-08-21
- Latest
- 2026-10-14
- Applications
- 7